News Roundup [abridged Versions Appear In The Paper Journal]

Trastuzumab wins backing of European drug regulator

BMJ 2006; 332 doi: (Published 04 May 2006) Cite this as: BMJ 2006;332:1050
  1. Clare Dyer, legal correspondent
  1. BMJ

    Trastuzumab (Herceptin), the breast cancer drug at the centre of a row over rationing in the NHS, last week won the first stage of approval by the European drug regulator for use in treating early stage cancer.

    A committee of the European Medicines Agency, which licenses drugs for European Union countries, backed the extension of the drug's licence to include early stage disease in a record 10 weeks from application.

    The recommendation, from the agency's committee for medicinal products for human use, is for the use of trastuzumab after surgery and …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription